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Purpose: Radiation therapy is a commonly used treatment for prostate cancer; however, the side effects may negatively affect
quality of life and cause patients to be less physically active. Although exercise has been shown to mitigate radiation therapy
−related fatigue in men with prostate cancer during radiation therapy, other adverse effects of treatment such as physical
deconditioning, urinary symptoms, or sexual dysfunction have not been systematically reviewed in this patient population.
Thus, the purpose of this review was to investigate the effect of exercise on physical function and treatment-related side
effects in men with prostate cancer undergoing radiation therapy.
Methods: A systematic literature search was conducted in the PubMed, Embase, CINAHL Plus, SPORTDiscus, and Web of
Science databases in December 2020. Included studies were randomized controlled trials examining the effects of aerobic
and/or resistance exercise interventions on measures of physical function and treatment-related side effects in prostate cancer
patients undergoing radiation therapy. Meta-analysis was performed on outcomes that were reported in 2 or more studies.
Results: Seven publications from 6 randomized controlled trials involving 391 prostate cancer patients were included.
Patients had stage I to IV cancer with a Gleason score of ≤6 to 10. Exercise resulted in consistent significant benefits for phys-
ical function in terms of cardiovascular fitness (standardized mean difference [SMD], 0.83; 95% confidence interval [CI],
0.31-1.36; P < .01) and muscle function (SMD, 1.30; 95% CI, 0.53-2.07; P < .01). Furthermore, there was a significant posi-
tive effect of exercise on urinary toxicity (SMD, −0.71; 95% CI, −1.25 to −0.18; P < .01), but not on intestinal (P = .21) or
hormonal toxicity (P = .41), depression (P = .45), or sleep symptoms (P = .88).
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Conclusion: Based on the current evidence, exercise in men with prostate cancer undergoing radiation therapy improves phys-
ical function and mitigates urinary toxicity. The effect of exercise on other treatment-related side effects are less clear and
require further investigation.  2021 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Introduction
Radiation therapy has undergone substantial advances over
the past century as a result of technological innovations that
have continually led to improvements in patient care. Better
radiation dose distribution resulting in superior tumor con-
trol while reducing treatment toxicity has benefitted
patients in terms of treatment outcome as well as quality of
life.1,2 In prostate cancer, radiation therapy is an effective
and commonly used treatment modality but, for some
patients, treatment may result in sexual dysfunction and can
cause bladder as well as bowel symptoms, which have been
shown to adversely affect the mental health and quality of
life of patients.3,4
The benefits of integrating exercise into cancer care, and
even directly into treatment centers, are increasingly being
recognized.5,6 Researchers have consistently demonstrated
that exercise may improve cancer- and treatment-related
health outcomes such as fatigue, quality of life, anxiety,
depression, bone health, lymphedema, physical function,
and sleep.7-9 However, in prostate cancer, the vast majority
of these studies have either focused on patients before and
after radical prostatectomy or to manage the known and
extensive side effect profile of patients receiving androgen
deprivation therapy (ADT), and very little attention has
been given to exploring whether there are potential benefits
of exercise in patients during radiation therapy alone.
In a recent meta-analysis examining the effect of exer-
cise training on fatigue and quality of life in prostate cancer
patients undergoing radiation therapy, exercise resulted in
significant benefits for fatigue but was found to have no sig-
nificant effect on quality of life.10 However, measures of
global quality of life have been found to not accurately rep-
resent the influence of disease or treatment-specific symp-
toms in prostate cancer patients, with global health status
being similar between previously treated prostate cancer
patients and a group of men with no history of prostate can-
cer in spite of greater urinary, bowel, and sexual dysfunc-
tion in the prostate cancer group.11 Thus, closer
investigation of more specific health-related outcomes
before and after prostate cancer treatment and whether exer-
cise programs can prevent, reduce, or aid the recovery of
these problems is warranted. Furthermore, the role of exer-
cise during radiation therapy and the effect on physical
function and other domains of health-related outcomes such
as depression or sleep quality as well as prostate cancer-
specific symptoms have not been systematically reviewed.
Therefore, the purpose of this review was to examine the
current evidence resulting from investigations of the effects
of exercise on physical function and treatment-related side
effects in men with prostate cancer undergoing radiation
therapy. In addition, we report on adverse events that
occurred in the trials to assess the safety of these exercise
interventions.
Methods and Materials
This systematic review followed the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses guide-
lines12,13 and was registered on PROSPERO (registration
no.: CRD42021228764). The search term strategy and
study eligibility criteria are based on the Population,
Intervention, Comparison, Outcomes, and Study design
framework (Table 1).
Search strategy
Systematic literature searches were conducted in the
PubMed, Embase, CINAHL Plus, SPORTDiscus, and Web
of Science databases in December 2020 using search terms
related to “prostate cancer,” “exercise,” and “radiation
therapy.” The full electronic search strategy is presented in
Table E1. A combination of keywords (search limited to
title and abstract) and subject index terms was used to
search all listed databases. No other limits such as date of
publication or article type were applied to the database
search. In addition, reference lists of all included publica-
tions and relevant review articles were checked for any
additional studies.
Identified records were imported into Covidence (Veritas
Health Innovation Ltd, Melbourne, VIC, Australia) where
duplicates were automatically removed. To exclude irrele-
vant records, titles and abstracts were first screened by one
reviewer (O.S.). Subsequently, full-text reports were further
reviewed independently by 2 researchers (O.S. and H.L.) to
assess eligibility. Any disagreements between the 2
reviewers were resolved through consensus.
Table 1 Components of Study Eligibility Criteria (Popula-
tion, Intervention, Comparison, Outcomes, and Study Design
Framework)
Component Description
Population Prostate cancer patients during radiation
Intervention Clinic- and/or home-based exercise
Comparison Usual care (ie, no formal exercise)
Outcomes Physical function and treatment toxicity
Study design Randomized controlled trials
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Eligibility criteria
Randomized controlled trials were included if: (1) a clinic-
and/or home-based resistance and/or aerobic exercise pro-
gram was conducted during the course of radiation therapy
in men with prostate cancer; and (2) outcomes of objec-
tively measured physical function (eg, cardiorespiratory fit-
ness, upper/lower body strength, or mobility) or treatment-
related side effects (eg, urinary and gastrointestinal toxicity,
sleep quality, or depression and anxiety) were reported.
Treatment-related side effects were defined as radiation
therapy toxicity or any patient-reported outcome or symp-
tom assessed by questionnaire response or clinician assess-
ment. However, fatigue and general quality of life were not
assessed as they were the subject of a recent meta-
analysis.10
Studies were excluded if: (1) mixed cancer cohorts were
investigated, unless data for prostate cancer patients were
reported separately, (2) exercise interventions were not per-
formed concurrently with radiation therapy, (3) not all
patients were undergoing radiation therapy at the time of the
exercise intervention, (4) study interventions consisted only
of holistic training modalities (such as yoga, qigong, or tai
chi) or specific rehabilitation techniques (eg, pelvic floor
muscle training), (5) no specific data were reported for the
outcomes of interest, (6) full-text articles were not available,
or (7) studies were reported in languages other than English.
Data extraction
Data extraction was performed independently by 2 review
authors (O.S. and H.L.) using a pre-established data extrac-
tion form. The form was piloted by O.S. and refined accord-
ingly. Finally, the following data items were extracted: (1)
study characteristics such as year of publication, sample
size, and study setting; (2) participant characteristics and
clinical information, including patient age, disease stage,
and treatment plan; (3) exercise intervention descriptors
such as program duration, exercise modality, training fre-
quency, intensity and duration; and (4) outcomes of interest
(including adverse events) for each group. Any disagree-
ments between the 2 reviewers were resolved by consensus.
Quality assessment
The methodological quality of included studies was
assessed using the Physiotherapy Evidence Database
(PEDro) scale.14 The PEDro scale consists of 11 items to
assess external (item 1) and internal (items 2-9) validity as
well as statistical reporting (items 10 and 11). All but the
first item that is satisfied contributes 1 point to the total
score, resulting in an overall score of 0 to 10 for each study.
However, given the nature of exercise trials, it is not possi-
ble to blind patients and research personnel administering
the intervention. Thus, a score of 8 on the PEDro scale was
considered to be the highest possible score attainable. The
score for methodological quality was rated as poor if 3 or
lower, fair if 4 to 5, and good if 6 or higher.15 All studies
were included in qualitative and quantitative data synthesis,
regardless of their PEDro score. The methodological qual-
ity assessment was independently performed by 2 review
authors (O.S. and H.L.) and any discrepancies were
resolved through consensus.
Statistical analysis
Meta-analysis was performed for outcomes that were
reported in 2 or more studies. Pooled effect estimates were
obtained from standardized mean differences (SMD) when
combining different scales of a comparable outcome,
whereas mean differences (MD) were used when combin-
ing studies with the same scale for a particular outcome.
Where outcomes were assessed at multiple timepoints, val-
ues were calculated from first assessment to assessment at
or earliest assessment after completion of radiation therapy.
“Cardiorespiratory fitness” was created as a composite out-
come using peak oxygen consumption (V̇O2peak), meta-
bolic equivalents (METs), and walking distance obtained
from either the 6-minute walk test or a modified shuttle
test. Time to complete the 5-repetition sit-to-stand test as
well as 8-repetition maximum leg and chest press perfor-
mance were combined to establish a “Muscle function” out-
come. “Depressive symptoms” were comprised of the Beck
Depression Inventory and Center for Epidemiological Stud-
ies Depression Scale. “Sleep problems” was a combination
of the European Organisation for Research and Treatment
of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-
C30 insomnia scale, the Pittsburgh Sleep Quality Index, the
Epworth Sleepiness Scale, and Insomnia Severity Index.
The Radiation Therapy Oncology Group (RTOG)/EORTC
acute radiation morbidity scale for bladder toxicity, the
EORTC QLQ-PR25 urinary symptoms scale, as well as the
Expanded Prostate Cancer Index Composite (EPIC) urinary
function score and American Urological Association
(AUA) Symptom Index were aggregated to form the
“Urinary toxicity” outcome. “Intestinal toxicity” was com-
prised of the same outcome measures as “Urinary toxicity”
with the corresponding scales/scores, but instead of the
AUA Symptoms Index it incorporated the EORTC QLQ-
C30 constipation and diarrhea scales. Finally, the EORTC
QLQ-PR25 hormonal treatment-related symptoms scale
and EPIC hormonal function score were combined to create
“Hormonal toxicity.” For reverse scaled physical function
outcomes (ie, where lower values indicate a better outcome)
and treatment-related side effects (ie, where higher values
indicate a better outcome), the mean values in each group
were multiplied by −1, as recommended in the Cochrane
Handbook for Systematic Reviews of Interventions,16 to
ensure same direction of measuring effects.
In studies comparing multiple exercise interventions to a
single control group, data from exercise groups were combined
according to recommendations by Borenstein et al.17
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Furthermore, where multiple comparable outcomes were
assessed in a single study, these outcomes were combined to
form a single composite measure of that outcome.18 Pooled
effect estimates were calculated using a random-effects model
with the DerSimonian-Laird method and considered statisti-
cally significant for P values less than .05.19 Heterogeneity
was assessed using Cochran’s Q and quantified with the I2 sta-
tistic. Heterogeneity was considered statistically significant for
P values less than .05 and I2 greater than 50% was considered
indicative of high heterogeneity.20 All data were analyzed
using R, version 4.1.0 (The R Foundation) with the packages
meta (version 4.18-1)21 and dmetar (version 0.0.9000).22
Results
Search results
Electronic database searching yielded a total of 1878 records.
After removal of duplicates (n = 405) and exclusion of nonrele-
vant references through title and abstract screening (n=1426), 47
full-text articles were assessed for eligibility. Of these, 8 publica-
tions describing 6 trials met the eligibility criteria (Fig. 1). How-
ever, one publication23 from the study by Hojan et al24 was
excluded from the analysis and is not further discussed in this sys-
tematic review, as it only reported additional results after the
Articles eligible for systematic review 
(n=8)
Articles included in qualitative synthesis 
(n=7)
Records identified through database searching 
(n=1878)
Records screened by title and abstract 
(n=1473)






  Articles excluded (n=39), with reasons:
Conference abstract (n=25)
Mixed patient population (n=9)
Duplicate article (n=1)
No control group (n=1)
Outcome of interest notreported (n=1)
Patients not currently undergoing
radiotherapy (n=1)
Non-English article (n=1) 
  Articles excluded (n=1), with reasons:
Duplicate reporting of results (n=1)
Fig. 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram.
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completion of radiation therapy compared with the initial study
report.24 Thus, a total of 7 publications describing 6 trials were
ultimately included in this systematic review.
Study characteristics
The characteristics of included studies are presented in
Table 2. Reports were published between 2004 and 2020,
and trials included a total of 391 prostate cancer patients
(range, 21-121 patients). Patients were diagnosed with stage
I to IV prostate cancer with Gleason scores ranging from ≤6
to 10. All patients were treated with radiation therapy with
or without hormone therapy.
Exercise interventions were either home-based,25 con-
ducted in a clinic setting,24,26-28 or a combination of both.29
A detailed description of individual exercise programs used
in each study is presented in Table E2. Exercise programs
were 4 to 24 weeks in duration with most being ≤8 weeks
and usually depended on duration of radiation therapy
received. Programs consisted of either aerobic only exercise
such as walking or cycling,25-28 resistance training only,27-
29 or a combined aerobic and resistance training regimen.24
Exercise sessions lasted between 25 to 55 minutes with a
frequency of 3 to 5 times per week. Aerobic exercise inten-
sity was 60% to 70% of age-predicted maximal heart
rate,24,25 65% of heart rate reserve,26 or 50% to 75% of
V̇O2peak,
28 and 60% to 75% of 1-repetition maximum24,28
or 4 to 6 rating of perceived exertion on the 10-point modi-
fied Borg scale27 for resistance training. Furthermore, resis-
tance training was performed for 1 to 3 sets of 8 to 12
repetitions for 5 to 10 different exercises targeting major
muscle groups. Patients in one study performed high-inten-
sity interval training at heart rates at and above 85% of age-
predicted maximum,27 and the resistance training group in
another study served as an active control group rather than
an actual intervention group, thus, the intensity was low.29
Quality assessment
The PEDro quality assessment of included randomized con-
trolled trials is shown in Table 3. Methodological quality
was rated as “good” overall, with a median PEDro score of
6.5 (range, 4-7). Four24,25,27,28 out of 6 trials were deemed
to have good methodological quality (ie, scores ≥6 on the
PEDro scale).
Effects of exercise on physical function
Five studies included assessment of physical function
before and after radiation therapy in men with prostate can-
cer.24-28 Functional exercise capacity/cardiorespiratory fit-
ness was assessed in all 5 trials by either measuring
walking distance,24,25,27 METs,24,26 or V̇O2peak.
28 Meta-
analysis of pooled outcomes showed a significant effect of
exercise (SMD, 0.83; 95% confidence interval [CI], 0.31-
1.36; P < .01) (Fig. 2A). The study by Windsor et al25 was
considered an outlier and was omitted from the result for
the effect of cardiorespiratory fitness. In studies assessing
walking distance, test performance was significantly
improved in aerobic,25,27 resistance,27 and mixed modal-
ity24 training groups compared with usual care. The 2 stud-
ies assessing METs reported conflicting results; functional
capacity calculated based on a treadmill test using a modi-
fied Bruce protocol significantly increased by 2.6 § 0.9
METs (P < .001) with 8 weeks of aerobic exercise (ie,
walking) compared with no change in the control group
(−0.2 § 2.5 METs; P = .77),26 whereas 8 weeks of com-
bined aerobic and resistance training showed no significant
difference between groups after radiation therapy, nor any
within-group changes, in METs derived from the 6-minute
walk test.24 In the study by Segal et al,28 aerobic exercise as
well as resistance training prevented a decline in V̇O2peak.
However, a significant difference was only observed
between the resistance training and control groups (1.5 mL/
kg/min; 95% CI, 0.06-3.0 mL/kg/min; P = .041), with the
difference between the aerobic exercise and control group
being similar in magnitude but statistically not significant
(1.4 mL/kg/min; 95% CI, −0.01 to 2.8; P = .052).28
Lower-body strength was assessed in 2 studies.26,28
Monga et al26 found that an 8-week walking program
resulted in superior performance on the 5-repetition sit-to-
stand test, whereas Segal et al28 reported that only the resis-
tance training group had increased 8-repetition maximum
leg press performance after 24 weeks of training compared
with the control group, with no change in the aerobic exer-
cise training group. Segal et al28 also assessed upper-body
strength using 8-repetition maximum chest press perfor-
mance, which was improved in the resistance training
group, unchanged in the aerobic exercise group and
declined in the control group. Consequently, between-group
differences in upper-body strength were significant for both
exercise groups compared with the usual care group. For
combined upper- and lower-body muscle function, meta-
analysis showed a significant effect of exercise (SMD, 1.3;
95% CI, 0.53-2.07; P < .01) (Fig. 2B). Furthermore, Monga
et al26 reported increased flexibility as assessed by a modi-
fied sit-and-reach test in the exercise group with no change
in the control group.
Effects of exercise on treatment toxicity
Treatment-related side effects before and after radiation
therapy in men with prostate cancer were investigated in 6
studies.24,26-30 An overview of the studies, including when
which outcomes were assessed in relation to radiation ther-
apy, is presented in Figures 3 to 5. Prostate cancer-specific
symptoms were assessed in 5 studies by a variety of meas-
ures (Fig. 3); 2 studies used the Functional Assessment of
Cancer Therapy-Prostate (FACT-P) questionnaire,26,28 1
study used the EORTC QLQ-C30 in combination with the
EORTC QLQ-PR25,24 another study used the EPIC and
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Table 2 Characteristics of Included Studies and Overview of Results






Key findings (exercise vs
control)y
Windsor et al25 n=66
Ex: 33; Con:
33




50 or 52 Gy in 20






(4 wk): ≥3 times/wk at
60%-70% HRmax for 30
minutes
100% adherence
n = 1 (1.5%) dropout
Ex: 1; Con: 0
"Modified shuttle test walk
distance
Monga et al26 n = 21
Ex: 11; Con:
10
Mean age: 69.2 §




Gleason score: 5.3 § 1.1
68-70 Gy in 34-38
fractions over 7-8 weeks
Clinic-based aerobic exercise
program
(8 wk): 3 times/wk at 65%
HRreserve for 30 minutes
Adherence and/or
attendance not reported










Segal et al28 n = 121
RT: 40; AE:
40; Con: 41













(24 wk): 3 times/wk at
50%-75% V̇O2peak for 15-
45 minutes or 60%-70%
1RM for 2 sets of 8-12
repetitions
88% attendance in RT
group and
83% attendance in AE
group
n = 11 (9.1%) dropout














Kapur et al30 See Windsor et al25 above Rectal toxicity:
#Mean rectal toxicity over 4
weeks of radiation therapy
$ Rectal toxicity at weekly
treatment review
$ Rectal toxicity at 4 weeks
postradiation therapy
Bladder toxicity:
$Mean bladder toxicity over
4 weeks of radiation therapyx













































Key findings (exercise vs
control)y
# Bladder toxicity at 4 weeks
postradiation therapyx
Hojan et al24 n = 55
Ex: 27; Con:
28














(8 wk): 5 times/wk at 65%-
70% HRmax for 30 minutes
and 70%-75% 1RM for 2
sets of 8 repetitions
95% attendance
n = 1 (1.8%) dropout
Ex: 0; Con: 1
Physical function:












# Problems with wearing an
incontinence aid
McQuade et al29 n = 50{
Ex: 26; Con:
24





75-76 Gy in 36-42








(6-8 wk): 3 times/wk for 8-
12 repetitions per set
100% attendance in
63.5% of patients and
>50% attendance in
80.8% of patients
n = 9 (18%) dropout





$ Prostate symptom score
Piraux et al27 n = 78
HIIT: 27; RT:
25; Con: 26




Gleason score: 7.8 § 0.9
(range, 7-10)
62-78 Gy in 26-39





19% had a previous
prostatectomy
Clinic-based aerobic exercise
(HIIT) or resistance training
program
(5-8 wk): 3 times/wk at
65% to ≥85% HRmax for
16-30 minutes (8-15
intervals) or 4-6 RPE for 1-
3 sets of 8-12 repetitions
93.5% attendance in HIIT
group and
91.4% attendance in RT
group
n = 6 (7.7%) dropout
HIIT: 3; RT: 1; Con: 2
Physical function:







Abbreviations: 1RM = one-repetition maximum; AE = aerobic exercise; Con = control group; EORTC = European Organisation for Research and Treatment of Cancer; Ex = exercise group; HIIT = high-
intensity interval training; HRmax = maximal heart rate; HRreserve = heart rate reserve; MET = metabolic equivalent of task; RPE = rating of perceived exertion; RT = resistance training; QLQ-C30 = Quality of
Life Questionnaire; QoL = quality of life; V̇O2peak = peak oxygen uptake.
* Detailed exercise prescriptions are presented in Table E2.
y Results are presented for between-group differences (P<.05): ", significant increase with exercise vs control; #, significant decrease with exercise vs control; $, no significant difference between exercise
and control.
z Out of 30 patients randomized.
x Three patients in the exercise group had indwelling urinary catheters during the course of their treatment and were excluded from the analysis for bladder toxicity.
k As assessed by the EORTC QLQ-C30: nausea and vomiting, pain, dyspnoea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties.








































AUA Symptom Index,29 and 1 study assessed clinician-
graded bladder and rectal toxicity using the RTOG/EORTC
acute radiation morbidity scale.30
Monga et al26 found that the total FACT-P score
increased after the exercise intervention, indicating
improved quality of life, compared with the control group.
However, there was no significant difference in this study
for the prostate cancer subscale that assesses prostate can-
cer-specific symptoms.26 Furthermore, prostate cancer-spe-
cific symptoms as assessed by the corresponding subscale
on the FACT-P questionnaire decreased (ie, worsened) by
−1.91 to −4.17 points (mean change across all groups;
P = .047 to P < .001) after 12 weeks of the intervention in
the study by Segal et al,28 regardless of group allocation but
recovered again to baseline levels after 24 weeks. Pooled
results of meta-analysis showed a borderline significant
effect of exercise (MD, 2.15; 95% CI, −0.06 to 4.35;
P = .06) (Fig. 6A).
Moreover, no significant differences between exercise
and control were reported by McQuade et al29 for any of
the EPIC domains, including urinary, bowel, and hormonal
function, or the AUA prostate symptoms score. These
Table 3 Quality Assessment of Included Randomized Controlled Trials
Assessment criteria*
Study 1 2 3 4 5 6 7 8 9 10 11 Total scorey
Windsor et al25 Y Y Y Y N N N Y Y Y Y 7
Monga et al26 Y Y N Y N N N N Y Y Y 5
Segal et al28 Y Y Y Y N N N Y Y Y Y 7
Hojan et al24 Y Y Y Y N N N Y Y Y Y 7
McQuade et al29 Y Y N N N N N N Y Y Y 4
Piraux et al27 Y Y N Y N N N Y Y Y Y 6
Abbreviations: N = no; Y = yes.
* Assessment criteria of the PEDro scale: (1) eligibility criteria were specified; (2) particpants were randomly allocated to groups; (3) allocation was
concealed; (4) groups were similar at baseline; (5) participants were blinded; (6) therapists who administered the therapy were blinded; (7) assessors
were blinded; (8) measures of at least 1 key outcome were obtained from >85% of participants; (9) participants received treatment or control condition
as allocated or data was analyzed by intention to treat; 10) statistical comparisons between groups were reported; and 11) point measures and measures of
variability were provided.
y Criterion 1 (ie, “eligibility criteria were specified”) relates to external validity and is not used to calculate the total PEDro score.14
Total (95% CI)
Heterogeneity: Tau2 = 0.1956; Chi2 = 10.41, df = 3 (P = 0.02); I2 = 71%
Test for overall effect: Z = 3.10 (P < 0.01)
198 135 100.0% 0.83 [ 0.31; 1.36]
3 2 1 0 1 2 3
Std. Mean Difference
IV, Random, 95% CI
Favours [Control] Favours [Exercise]
Study
Total (95% CI)
Heterogeneity: Tau2 = 0.1861; Chi2 = 2.11, df = 1 (P = 0.15); I2 = 53%
Test for overall effect: Z = 3.32 (P < 0.01)
Segal et al. (2009)
































2 1 0 1 2
Std. Mean Difference
IV, Random, 95% CI
Favours [Control] Favours [Exercise]
A. Cardiorespiratory fitness
B. Muscle function
Exercise Control Std. Mean Difference
Study Mean SD Total Mean SD Total Weight IV, Random, 95% CI
Piraux et al. (2021) 33.10 74.34 48 3.20 71.55 24 27.9% 0.40 [ 0.09; 0.90] 
Segal et al. (2009) 0.09 3.35 80 1.40 3.27 41 31.0% 0.45 [ 0.06; 0.83] 
Hojan et al. (2016) 15.03 18.65 27 11.87 19.57 27 25.0% 1.39 [ 0.79; 1.98] 
Monga et al. (2007) 2.60 0.90 11 0.20 2.50 10 16.1% 1.46 [ 0.47; 2.45] 
Windsor et al. (2004) 67.50 29.33 32 11.50 21.70 33 0.0% 3.03 [ 2.31; 3.76]
Fig. 2. Effects of exercise compared with usual care on cardiorespiratory fitness (A) and muscle function (B).
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results are consistent with outcomes from the meta-analy-
sis, except for the urinary domain (Fig. 6B-D). For urinary
toxicity, there was a significant benefit of engaging in exer-
cise compared with the usual care control group when pool-
ing study outcomes (SMD, −0.71; 95% CI, −1.25 to
−0.18; P < .01) (Fig. 6B).
The EORTC QLQ-C30 is a questionnaire that is not
prostate cancer-specific but includes symptom subscales
such as pain or diarrhea that are nevertheless relevant to
prostate cancer. In the study by Hojan et al,24 however,
there were no significant differences for any of these symp-
toms, except for a significant within-group change in diar-
rhea. In the control group, diarrhea significantly increased
by 11.5 § 32.7 points (P ≤ .05) after treatment compared
with pretreatment levels, and, although not statistically sig-
nificant, there was a similar magnitude of increase regard-
ing symptoms of diarrhea (10.8 § 18.9 points) in the
exercise group.24 Similarly, problems associated with wear-
ing an incontinence aid increased in both groups after 8
weeks of radiation therapy and exercise or usual care (9.1
§ 24.3 and 12.2 § 38.5 points, respectively; P ≤ .05), but
to a significantly lesser extent in the group doing combined
aerobic and resistance training throughout treatment
(between-group mean change, −3.1 points in favor of exer-
cise; P < .05).24 Urinary symptoms, however, were signifi-
cantly lower in the exercise group after radiation therapy
compared with the control population (31.8 § 16.2 vs 48.9
§ 20.7 points; P ≤ .01), in that exercise prevented an
increase in symptom burden (1.9 § 18.5 points; P > .05)
that was seen in the control group (16.4 § 16.0 points; P ≤
.01).24 As observed with urinary symptoms, there was also
a decrease in sexual functioning in the nonexercise control
group after treatment (−9.7 § 36.4 points; P ≤ .05) that
was not seen in the intervention group (0.6 § 41.4 points; P
> .05).24
In contrast to other studies included in this systematic‘
review, Kapur et al30 did not use self-administered ques-
tionnaires to assess prostate cancer treatment−related side
effects, but rather analyzed acute radiation morbidity scor-
ing for bladder and rectal toxicity, which were prospec-
tively recorded but retrospectively extracted from patient
records at weekly treatment reviews. Although rectal toxic-
ity was comparable between groups at these weekly assess-
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Bladder toxicity at follow-up
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weeks of radiotherapy
Fig. 3. Overview of studies with assessment of prostate cancer-specific outcomes. Results are presented for between-group
differences (P < .05): ", significant increase with exercise vs control; #, significant decrease with exercise vs control; $, no
significant difference between exercise and control. Continuous lines with arrows indicate the duration of radiation therapy.
Where variable durations of radiation therapy were reported, continuous lines represent the shortest and dashed lines represent
the longest duration of radiation therapy reported. Vertical arrows represent timepoints of outcome assessments (dashed verti-
cal arrows correspond with the assessment timepoints for the longest duration of radiation therapy reported). If specific inter-
vals for assessment timepoints before/after the start/end of radiation therapy were indicated, these are shown accordingly (eg,
in the study by Hojan et al,24 it was reported that outcomes were assessed 1 week before/after the start/end of radiation ther-
apy, respectively). Where no precise assessment timepoints were reported (ie, at baseline before radiation therapy and after
the end of radiation therapy, or similar), we assumed that assessments were performed shortly before/after the start/end of
radiation therapy. Hence, for these studies, assessment timepoints are shown at the start/end or radiation therapy. Abbrevia-
tions: AUA, American Urologic Association; EORTC, European Organisation for Research and Treatment of Cancer;
FACT-P, Functional Assessment of Cancer Therapy-Prostate; RTOG, Radiation Therapy Oncology Group; QLQ, Quality of
Life Questionnaire.
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follow-up 4 weeks after treatment, the mean rectal toxicity
scores over the 4 weeks of treatment were significantly
lower in the exercise group, who were provided with a
home-based walking program, compared with the usual
care control group (0.91 § 0.52 vs 1.27 § 0.46; mean dif-
ference, −0.36; 95% CI, −0.61 to −0.12; P = .004).30 In
addition, bladder toxicity was also significantly lower in the
exercise group at the follow-up assessment 4 weeks post
radiation therapy (1.17 § 0.38 vs 1.73 § 0.84; mean differ-
ence, −0.56; 95% CI, −0.89 to −0.27; P = .001).30
Depressive symptoms were assessed in 2 studies using
either the Beck Depression Inventory or the Center for Epi-
demiological Studies Depression Scale (Fig. 4).26,27 No sig-
nificant difference between the usual care and exercise
groups, which consisted of either walking on a treadmill26;
high-intensity interval training on a cycle ergometer27; or
resistance training using body weight, resistance bands, and
dumbbells was reported.27 Moreover, there were no signifi-
cant within-group changes in either study.26,27 Meta-analy-
sis of pooled studies also revealed no significant benefit of
exercise on depressive symptoms (SMD, −0.16; 95% CI,
−0.59 to 0.26; P = .45) (Fig. 7A).
Sleep quality (Pittsburgh Sleep Quality Index), daytime
sleepiness (Epworth Sleepiness Scale), and the severity of
insomnia (Insomnia Severity Index) were assessed in 2
studies (Fig. 5).27,29 No significant differences or within-
group changes were observed for any of the sleep domains
with either resistance27,29 or high-intensity interval train-
ing27 compared with usual care. Pooled meta-analysis of all
3 outcome measures also indicated no significant effect of
exercise on sleep (SMD, 0.02; 95% CI, −0.29 to 0.34;
P = .88) (Fig. 7B).
Adverse events
For 3 of the 6 trials,24,27,28 information about adverse events
was reported. One study27 recorded no exercise-related
adverse events, whereas the other 2 studies24,28 reported a
total of 4 adverse events. In the study by Hojan et al,24 1
patient in the control group experienced a stroke and was
excluded from the analysis. In the study by Segal et al,28 3
adverse events occurred in the 2 exercise groups. One
patient in the aerobic exercise group experienced an acute
myocardial infarction shortly after completing the third
exercise session. The patient was resuscitated and fully
recovered but did not complete the study. The patient who
experienced the myocardial infarction had no previous car-
diac history. A second patient in the aerobic exercise group
had syncope before treadmill exercise testing, and 1 patient
in the resistance training group experienced chest pain dur-
ing exercise. For both patients with syncope and chest pain,
no underlying causes were identified.
Discussion
In this systematic review, we provide a comprehensive
assessment of the current literature with regard to exercise
training during radiation therapy treatment in men diag-
nosed with prostate cancer and the effect on physical func-
tion and treatment-related adverse effects. The studies
indicate that exercise may be beneficial to improve multiple
aspects of physical function such as cardiorespiratory fit-
ness and muscle strength, as well as mitigate urinary
Depressive symptoms
Beck Depression Inventory 
68-70 Gy in 34-38 fractions over 7-8 weeksTreatment
Outcome sampling 
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62-78 Gy in 26-39 fractions over 5-8 weeks; 
81% receiving neoadjuvant and adjuvant hormone therapy; 
19% had previous prostatectomy
Piraux et al. 
(2021)27
Assessment method Results
Fig. 4. Overview of studies with assessment of depressive symptoms. Results are presented for between-group differences
(P < .05): ", significant increase with exercise vs control; #, significant decrease with exercise vs control; $, no significant
difference between exercise and control. Continuous lines with arrows indicate the duration of radiation therapy. Where vari-
able durations of radiation therapy were reported, continuous lines represent the shortest and dashed lines represent the lon-
gest duration of radiation therapy reported. Vertical arrows represent timepoints of outcome assessments (dashed vertical
arrows correspond with the assessment timepoints for the longest duration of radiation therapy reported). If specific intervals
for assessment timepoints before/after the start/end of radiation therapy were indicated, these are shown accordingly (eg, in
the study by Piraux et al,27 it was reported that outcomes were assessed 10 days before the start of radiation therapy). Where
no precise assessment timepoints were reported (ie, at baseline before radiation therapy and after the end of radiation therapy,
or similar), we assumed that assessments were performed shortly before/after the start/end of radiation therapy. Hence, for
these studies, assessment timepoints are shown at the start/end or radiation therapy.
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toxicity. In contrast, there is no evidence of an effect of
exercise on other side effects commonly associated with
prostate cancer treatments that include radiation therapy
such as intestinal toxicity, depressive symptoms, or sleep
problems.
The most evident benefits of exercise were improve-
ments in physical function. All included studies and exer-
cise modalities resulted in increased performance of at least
1 domain of physical function, including cardiorespiratory
fitness, upper- and lower-body muscle strength, and flexi-
bility. Although not assessed in the majority of included
studies, these improvements are likely to translate into
increased performance of functional tasks or at least
enhance patients’ physical reserve capacity. This is impor-
tant as it may allow patients to remain independent and per-
form activities of daily living without any significant
restrictions. In particular, a decline in musculoskeletal fit-
ness secondary to loss of lean mass with ageing and acceler-
ated by ADT is believed to contribute to a reduced physical
reserve capacity that may be prevented or even reversed by
targeted resistance training.31 Moreover, exercise has been
shown to reduce the rate of falls in older people32 and is an
important strategy in osteoporosis management,33 thus
reducing the risk of fractures, a concern particularly rele-
vant for men treated with ADT.34 In addition, worse out-
comes on physical performance tests have been associated
with treatment-related complications and reduced survival
in cancer patients.35 Hence, improving or maintaining phys-
ical function via structured exercise is of high clinical
importance in this patient population.
Declining neuromuscular efficiency and mitochondrial
dysfunction have also been implicated with fatigue,36,37 a
major debilitating side effect of radiation therapy that can
persist for some time after treatment.36 This highlights the
importance of improving or at least maintaining current aer-
obic capacity and muscular strength through exercise to
potentially mitigate the onset and/or severity of fatigue.
However, fatigue may be the result of various other poten-
tial causes36,38 and has also been correlated with late uri-
nary and rectal toxicity in men with prostate cancer after
radiation therapy, possibly owing to their negative effect on
sleep,39 thus emphasizing the need to address fatigue as a
multietiological problem.
Findings regarding the effects of exercise on gastrointes-
tinal and genitourinary toxicity in our review are conflict-
ing, however, and allow only limited comparability because
of the various assessment methods and timepoints used to
investigate these symptoms, the heterogeneity of the patient
population, and the different radiation doses and treatment
combinations used. Although no significant effects of exer-
cise were observed in the study by McQuade et al,29 the
correlation between physical symptoms (ie, urinary, bowel,
and hormonal toxicity) and fatigue, as well as sleep quality,
was also demonstrated for acute symptoms in exploratory
analyses. In addition, bowel symptoms and urinary function
have been shown to negatively affect physical activity lev-
els in men with prostate cancer.40,41 The resulting sedentary
lifestyle may lead to development or aggravation of other
chronic comorbidities that may further affect quality of life.
On the other hand, physician-graded bladder and rectal tox-
icity, an arguably more objective measure than patient-
reported outcomes,42 was significantly lower in the exercise
group in 1 study comparing home-based exercise to usual
care.30 Furthermore, despite significantly worse prostate
cancer-specific symptoms in all groups at 12 weeks in the
study by Segal et al,28 the scores in the resistance training
group did not constitute a clinically meaningful change,43
highlighting a further potential benefit of this exercise
Sleep problems
Pittsburgh Sleep Quality Index
Epworth Sleepiness Scale
Insomnia Severity Index
Pittsburgh Sleep Quality Index
Time (weeks)
4 5 6 7 8 12 240
+ assessment at 3 months post-radiotherapy
75-76 Gy in 36-42 fractions over 6-8 weeks; 
73.3% receiving adjuvant hormone therapy
62-78 Gy in 26-39 fractions over 5-8 weeks; 
81% receiving neoadjuvant and adjuvant hormone therapy; 
19% had previous prostatectomy
McQuade et al. 
(2017)29






Fig. 5. Overview of studies with assessment of sleep problems. Results are presented for between-group differences (P <
.05): ", significant increase with exercise vs control; #, significant decrease with exercise vs control; $, no significant differ-
ence between exercise and control. Continuous lines with arrows indicate the duration of radiation therapy. Where variable
durations of radiation therapy were reported, continuous lines represent the shortest and dashed lines the longest duration of
radiation therapy reported. Vertical arrows represent timepoints of outcome assessments (dashed vertical arrows correspond
with the assessment timepoints for the longest duration of radiation therapy reported). If specific intervals for assessment
timepoints before/after the start/end of radiation therapy were indicated, these are shown accordingly (eg, in the study by
McQuade et al,29 it was reported that outcomes were assessed during the last week of radiation therapy). Where no precise
assessment timepoints were reported (ie, at baseline before radiation therapy and after the end of radiation therapy, or similar),
we assumed that assessments were performed shortly before/after the start/end of radiation therapy. Hence, for these studies,
assessment timepoints are shown at the start/end or radiation therapy.
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modality that warrants further investigation. One caveat is
that the radiation therapy regimen was not reported in this
study. Thus, radiation for higher stage prostate cancer may
have been for metastatic disease, which would have
possibly not affected bladder, bowel, or sexual function as
radiation was not directed to the pelvis. However, only 1
patient had stage IV prostate cancer, and that patient was
allocated to the control group; the proportion of stage III
Study
Total (95% CI)
Heterogeneity: Tau2 = 0; Chi2 = 0.59, df = 1 (P = 0.44); I2 = 0%
Test for overall effect: Z = 1.91 (P = 0.06)
Segal et al. (2009)
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Fig. 6. Effects of exercise compared with usual care on prostate cancer-specific symptoms (A), urinary toxicity (B), intesti-
nal toxicity (C), and hormonal treatment-related toxicity (D). Abbreviation: FACT-P = Functional Assessment of Cancer
Therapy-Prostate.
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prostate cancer patients was actually higher in the aerobic
exercise (22.5%) and resistance training (20.0%) groups
compared with the usual care group (9.8%).28
Based on the included studies, it was not possible to
make any conclusions about long-term or late side effects
of radiation therapy as study outcomes were only assessed
immediately pre- and postradiation therapy or a couple of
weeks after radiation therapy. However, Dieperink et al44
conducted a multidisciplinary rehabilitation study assessing
prostate cancer-specific outcomes after patients had com-
pleted radiation therapy and recently published 3-year fol-
low-up data of this trial.45 Initial results 6 months post
radiation therapy demonstrated improved urinary symptoms
compared with usual care, although these were not sus-
tained at later follow-up. However, the beneficial effect of
the intervention was maintained at 3 years for the urinary
irritative subscale score in patients with moderate-to-severe
problems at baseline (ie, after radiation therapy). Further-
more, moderate-to-severe bowel problems were more prev-
alent in the control group than in the intervention group
after 3 years. As the intervention included pelvic floor train-
ing, incorporating exercises to strengthen pelvic floor
muscles alongside aerobic and resistance training may be
required to maintain adequate function in this population.
Cardiometabolic dysfunction and related diseases are a
common occurrence in men with prostate cancer and are
linked to a host of other complications.46-49 For example,
prostate cancer patients with unmanaged type 2 diabetes
and patients receiving insulin for treatment have been
identified as having an increased risk of both early and late
gastrointestinal and genitourinary toxicity after radiation
therapy compared with those patients not diagnosed with
diabetes.50 Prescribing exercise as medicine is an effective
therapy for the management of diabetes, for which exercise
has been shown to increase insulin sensitivity and improve
glycemic control.51,52 It may well be that exercise medicine
could reduce gastrointestinal and genitourinary toxicity
after radiation therapy in prostate cancer patients with dia-
betes. However, more research is required to investigate
these relationships.
Reports of the effects of exercise on sexual activity and
function are conflicting. In the study by Hojan et al,24 the
only research to assess sexual health included in this sys-
tematic review, there was a decrease in sexual function
with usual care that was not observed in the exercise inter-
vention group, whereas there was no significant effect on
sexual activity. This finding is in line with observational
data showing that more physical activity was positively
associated with better sexual function,53 including active
men having better erectile function than inactive men.41
However, recent contrasting reports indicate that a struc-
tured exercise program had no significant beneficial effect
on sexual function in men with prostate cancer undergoing
treatment,54,55 although exercise resulted in maintenance of
sexual activity levels.56 Nevertheless, exercise may appear
to be a potentially promising intervention to address sexual
dysfunction in prostate cancer patients via protective or
restorative effects on vascular function.57
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Fig. 7. Effects of exercise compared with usual care on depressive symptoms (A) and sleep problems (B).
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Psychological distress is also a significant issue in
men with prostate cancer and related treatment side
effects.58,59 Furthermore, higher levels of depressive
symptoms have been associated with decreased physical
activity and a lower likelihood of meeting the recom-
mendations of national physical activity guidelines.60
Among the studies assessed in this systematic review,
depressive symptoms and sleep variables such as day-
time sleepiness, insomnia, and sleep quality were not
affected by the exercise interventions. However, treat-
ment of patients with radiation therapy only has been
associated with a lower risk of depression compared
with ADT in men treated for recurrent prostate cancer,61
thus the potential benefit of exercise may have been too
small to detect in the investigated patient population,
given the presumably relatively low level of depressive
symptoms present. Indeed, symptoms of psychological
distress improved the most after exercise in patients
with prostate cancer receiving ADT who experienced
the highest level of anxiety, depression, and somatiza-
tion.62 Moreover, a reduction in psychological distress
was achieved with various supervised exercise modali-
ties, including aerobic exercise, resistance training, and
impact loading.62
Based on the analysis from this systematic review, it was
not possible to provide specific exercise recommendations
for prostate cancer patients during radiation therapy regard-
ing select outcomes; however, general exercise guidelines
for patients affected by cancer include evidence-based rec-
ommendations and specific exercise prescriptions for a
number of outcomes such as fatigue, depressive symptoms,
or physical function.8,9 Nevertheless, it is recommended
that an individualized assessment and exercise prescription
process be adopted.9 In general, a multimodal, moderate to
high intensity exercise program will be appropriate,
although individual patient circumstances, including any
accompanying health issues and exercise-related patient
preferences and goals, should be considered and exercise
prescriptions adapted accordingly.9
This review has some limitations that are worthy of com-
ment. Owing to the small number of studies assessing spe-
cific domains of physical function as well as the
heterogeneity of assessment tools used for patient-reported
outcomes, there is considerable heterogeneity in the quanti-
tative analysis of the results, thus reducing the robustness
of the findings. We also acknowledge that some treatment-
related side effects could be due to either radiation therapy,
ADT, or both, thus prohibiting an analysis of how exercise
may affect side effects purely arising as a consequence of
radiation. Furthermore, considerable variability existed
regarding the exercise prescription across studies, prevent-
ing recommendations of a specific intervention for select
outcomes. However, the strength of this review is the com-
prehensive assessment of current evidence regarding the
effects of exercise on unfavorable physical, psychological,
and psychophysical outcomes commonly experienced by
men with prostate cancer currently receiving radiation ther-
apy that may affect their quality of life and wellbeing.
The lack of conclusive evidence for patient-reported
outcomes may partially result from severe side effects
of treatment being rare and population summary statis-
tics therefore not reflecting any changes in subgroups
with significant toxicity. Even small reductions of these
significant toxicities by exercise would be valuable and
worthwhile to investigate in exploratory analyses of
future trials. We suggest that investigators consider
including toxicity outcomes of subgroups with moder-
ate-to-severe or significant side effects in their reports
(eg, as supplementary material) in addition to reporting
summary scores for the entire study population or indi-
vidual intervention groups. Given that minor toxicity is
irrelevant and moderate-to-severe toxicity is uncommon,
a classification like this may provide valuable insight
into the data, and investigators should use this philoso-
phy when they design their studies. A classification like
this may also allow comparability of endpoints between
different assessment tools to some degree, as they are
now “normalized” on a categorical level. Furthermore,
reporting of prostate cancer-specific endpoints such as
bladder and bowel problems or potency issues is heavily
influenced by the timepoints at which they are collected.
Given that these side effects get worse and may then
improve again, it is paramount that researchers sample
them at the correct and equivalent timepoints to prevent
the collection of potentially misleading data that does
not allow meaningful conclusions about a potential ben-
efit of exercise.
In conclusion, exercise during radiation therapy was safe
for prostate cancer patients in the included studies as evi-
dent by low rates of adverse events and resulted in signifi-
cant improvements in physical function and mitigation of
urinary symptoms, while not negatively affecting other
treatment toxicity outcomes such as intestinal symptoms,
depression, and sleep. On this basis, prostate cancer patients
should be informed about existing exercise programs and
should be encouraged to participate in regular structured
exercise training as part of supportive care during treat-
ment. However, further high-quality studies are required to
expand this field of enquiry and better understand the poten-
tial benefits of exercise during radiation therapy and how it
may counter treatment-related adverse effects. One such
example is the currently ongoing EXERT trial for men with
metastatic prostate cancer receiving palliative radiation
therapy (ClinicalTrials.gov: NCT04556045). Future
research may also investigate how the timing of exercise
(ie, during vs after radiation therapy) or different exercise
prescriptions (eg, comparing different exercise modalities
and intensities) may affect treatment toxicity, including
assessment of long-term follow-up of side effects as well as
potential mechanisms of action for exercise as an adjunct
therapy during radiation therapy in patients with prostate
cancer.63
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